GLP-1 receptor agonist
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
... The objective of this study was to identify factors that could predict the response to treatment at the time of the initiation of GLP-1 receptor agonist therapy. The non-response rate was ...
8
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
... of GLP-1 receptor agonist [5, 17] and metformin or com- bination of roflumilast and metformin [10], which might suggest a possible additive role of metformin to GLP-1 mediated ...
8
Efficacy and Safety of Basal Supported Prandial GLP 1 Receptor Agonist Therapy
... prandial GLP-1 receptor agonist therapy (BPT) may be effective and safe because of a lower risk of hypoglycemia and body weight gain ...
10
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
... EQW use over periods of .6 months has shown small favorable effects on cardiovascular risk factors and biomarkers. For instance, patients treated with EQW in the 30-week DURATION-1 study who continued open-label ...
10
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
... and GLP-1RAs address sev- eral of the defects seen in T2DM ...of GLP-1RA and basal insulin are potentially helpful tools for the treatment of patients with T2DM as a result of its favorable safety and ...
10
<p>The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date</p>
... The injectable formulation of semaglutide has an increased af fi nity for native human GLP1. Semaglutide molecule resembles native GLP1 sharing a 94% structural homology and is modi fi ed at 3 positions; position 8, where ...
12
Promotion of apoptosis in high glucose-activated hepatic stellate cells by GLP-1 receptor agonist and its potential mechanism.
... The apoptosis of activated HSCs is associated with complicated intracellular signaling pathways, and the involvement of MAPK signaling pathways has been analyzed in the greatest detail to date. The involvement of MAPKs ...
7
The arcuate nucleus mediates GLP 1 receptor agonist liraglutide dependent weight loss
... vagal GLP- 1Rs could play a role in the acute satiation process ...injected GLP-1 ...AP GLP-1Rs were ...vagal GLP-1Rs in only short-term satiation processes (34, 61, 62) as well as with ...
17
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
... The median PDC was significantly higher for exenatide once weekly (0.88) than for liraglutide once daily (0.77), particularly higher among patients between 51 years and 70 years of age (0.92 vs 0.79) (Table 2). The ...
5
Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
... a GLP-1 receptor agonist, only 17% were persistent with treatment (defined as the absence of a prescrip- tion gap of at least 90 days for either agent) during a 12-month period ...
9
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
... In the multi-trial GetGoal Program, the efficacy and safety of lixisenatide were investigated in different settings of type 2 diabetes therapy: either as monotherapy; as add-on therapy to metformin, sul- fonylureas, or ...
5
Fixed-Ratio Combinations
... Both FRCs are supplied as 3-mL prefilled pens. The wholesale acquisi- tion cost for five pens of iGlarLixi is $635 and for IDegLira is $953 (10). Using a mid-dose range of 35 units for a 30-day supply, the FRCs cost less ...
5
Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
... [8]. GLP-1 was shown to attenuate AGE-induced RAGE mRNA expression and oxidative stress in human proximal tubular epithelial [9] and mesangial cells ...[10]. GLP-1 receptor agonists are ...
9
Advances in the treatment of type 2 diabetes: impact of dulaglutide
... (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 ...a GLP-1 receptor agonist that mimics endogenous GLP-1, the hormone produced in ...
12
Liraglutide and obesity: a review of the data so far
... peptide 1 (GLP-1), may have potential as an antiobesity ...The GLP-1 receptor agonist, liraglutide (trade name Saxenda), was recently approved by the US Food and Drug ...
9
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
... GLP-1 receptor agonists are asso- ciated with a low rate of hypoglycemia and weight loss, whereas hypogly- cemia and weight gain are the main side effects associated with insulin ...a ...
10
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
... two GLP-1 receptor agonist medications, the most important factors in patients’ decisions in rank order were: “dosing frequency,” “type of delivery device,” “frequency of nausea,” “weight ...
12
Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure
... type 1 diabetes, ongoing treatment with inotropic agents, acute coronary syndrome or documented acute myocardial infarction within the previous 8 weeks, active myocarditis, significant aortic stenosis or mitral/ ...
9
The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling
... for agonist-docked GLP-1R that accounts for our current knowledge and that can also act as a basis for the design of new ligands and further ...of GLP-1R (Supplementary Figure S2; Supplementary Table ...
13
GLP 1 receptor agonists for Parkinson's disease (Protocol)
... (GLP-1) receptor agonists are a class of drugs that are licensed for the treatment of Type 2 diabetes (Baggio 2007; Campbell 2013; Doyle 2003; Holst ...An agonist acts by binding to a ...
14